40 results
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
develop;
injury to our reputation and significant negative media attention;
withdrawal of patients from clinical studies or cancellation of studies … to, successfully commercialize our product candidates.
S-29
If we use hazardous materials in a manner that causes injury, we could be liable
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
that we may develop;
injury to our reputation and significant negative media attention;
withdrawal of patients from clinical studies or cancellation … in our efforts to, successfully commercialize our product candidates.
S-29
If we use hazardous materials in a manner that causes injury, we could
424B5
2ve8jix
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
ffpltq lyt
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-10.1
e5nql3
30 Dec 21
Entry into a Material Definitive Agreement
4:37pm
424B5
29rhbji7 xv5q
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
2wrg4u
23 Jun 20
Prospectus supplement for primary offering
4:06pm
424B5
dsw82oqy
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
m0cb v5l7
22 Oct 19
Prospectus supplement for primary offering
4:24pm
424B3
rpdv9v91o0iz6d1q
12 Apr 19
Prospectus supplement
4:41pm